![]() He is a member of the Executive Global Leadership Group, and he serves as Secretary to the Board’s Audit and Risk Management Committee. CSL is a global biotechnology leader with business operations in more than 60 countries, and Greg has served as Group General Counsel since 2009. Greg Boss is responsible for worldwide legal operations for all CSL Limited Group companies. ![]() ![]() in Chemical Engineering from Carnegie Mellon University. in Chemical Engineering from the University of Pennsylvania and a Ph.D. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.ĭr. McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He transformed CSL's global end-to-end operations, advanced CSL Seqirus' differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. McKenzie became accountable for optimising CSL's operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses. McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation.Īfter joining CSL as Chief Operating Officer in 2019, Dr. Paul McKenzie was appointed Chief Executive Officer and Managing Director of CSL on 6 March 2023.ĭr. "Persistence has helped us to beat a difficult financing market," Ewert said.Dr. Some investors were unable to join this round because of timing difficulties, and discussions with them continue. Xerion was founded in 1998.Įwert added that the company expects to close additional funding within six months. The company is not yet profitable, but Ewert said that the target date for profitability is 2005. Over the medium term, Ewert sees the majority of the company's revenue coming from out-licensing opportunities on targets and compounds that are in clinical or preclinical testing. Xerion plans to bring most of its compounds into Phase II testing. Treatment will have to be after the fact, but able to address the condition," he said. "We want to be able to reach the responsible target with an antibody. It would be surprising if invasiveness were caused by different mechanisms," Ewert added.Īcute cardiovascular diseases, such as thrombosis and stroke, will comprise a second line of inquiry for the company. "Some proteins that are responsible for invasiveness have been found in several different cancer types. "In terms of indications," Ewert said, "we are focusing on the mechanisms underlying cancer metastasis." The company will investigate what makes a cell metastasize and try to find ways to inhibit this tendency. Ewert said those compounds are increasingly finding favor in the market and at major pharmaceutical companies, supplementing their traditional interest in small molecules. Xerion will base its pipeline on antibodies. "All in all, people have been extremely excited about our basic technology and our results so far," and that built investor confidence for moving to the development of therapeutic compounds. "The plan has always been to progress from technology to a therapeutic pipeline," Ewert said. The applications assist in target identification, deactivating selected proteins in a cell and functional site identification, respectively. The company's key products are Xcelerate, XCALIbur and X-plore. "It meets an important market need: to provide solidly characterized targets, with a causative relation between function and disease function." "Our investors have been thrilled about what our technology can provide," Markus Ewert, CEO of Martinsried-based Xerion, told BioWorld International. ![]() Existing investors 3i, Burrill & Co., IKB Venture Capital and BioM AG also participated in the round. The round of investment was co-led by Heidelberg Innovation, of Heidelberg, and Nextech Ventures, of Zurich, Switzerland, both of which are investing in Xerion for the first time. The company will use the funding to develop its own therapeutic pipeline, particularly in antibodies and acute cardiovascular diseases. MUNICH, Germany - Xerion Pharmaceuticals AG raised €12.3 million in its third round of financing, which it closed this week. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |